AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA BioTech ENLV Enlivex's Allocetra Cell Therapy For Knee Osteoarthritis Gets FDA's RMAT Designation; Stock Down July 13, 2026 — 10:41 am EDT Written by RTTNews.com for RTTNews -> (RTTNews) - Enlivex Ltd. (ENLV), a biopharmaceutical company developing macrophage reprogramming therapies, announced on Monday that the U.S. FDA has granted Regenerative Medicine Advanced Therapy or RMAT designation to Allocetra for the treatment of age-related symptomatic knee osteoarthritis. Allocetra is an off-the-shelf cell therapy comprising of apoptotic mononuclear cells derived from non-HLA matched donors, designed to modulate macrophage activity and restore immune balance. The FDA granted RMAT designation based on clinical evidence from the completed Phase 1/2a trial, which demonstrated significant and clinically meaningful improvements in knee pain and physical function, with efficacy lasting at least six months in patients with primary age-related osteoarthritis treated with Allocetra. Further, the FDA and the company have scheduled a Type B meeting to discuss the Allocetra development program and align on key elements of the planned Phase 2b trial. Osteoarthritis is a chronic degenerative joint disease characterized by the progressive breakdown of joint cartilage. According to the company, the condition affects an estimated 51.9 million adults in the U.S. and 527.8 million people worldwide. The company has initiated a randomized, controlled Phase 2b trial in the U.S. and the European Union based on the Phase 1/2a data. The study is expected to enroll about 182 patients with primary knee osteoarthritis data from the U.S. trial anticipated by the end of the second quarter of 2027. According to Intellectual Market Insights Research, the global knee osteoarthritis market size was valued at $5.9 billion in 2022, and is projected to reach $13.14 billion by 2031, growing at a compound annual growth rate, or CAGR, of 9.3%. ENLV closed Friday's trade at $6.86, down 7.30%. ENLV is currently down 2.92% to $6.66. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags BioTech RTTNews Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. More articles by this source -> Stocks mentioned ENLV More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.